These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17939293)

  • 21. Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4.
    Haas K; Johannes C; Geisen C; Schmidt T; Karsunky H; Blass-Kampmann S; Obe G; Möröy T
    Oncogene; 1997 Nov; 15(21):2615-23. PubMed ID: 9399649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions.
    Pelisson I; Soler C; Pechoux C; Chignol MC; Viac J; Euvrard S; Chardonnet Y
    J Dermatol Sci; 1992 Jan; 3(1):56-67. PubMed ID: 1317208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of KLF4 in UVB-induced murine skin tumor development and its correlation with cyclin D1, p53, and p21(Waf1/Cip1) in epithelial tumors of the human skin.
    Choi WJ; Youn SH; Back JH; Park S; Park EJ; Kim KJ; Park HR; Kim AL; Kim KH
    Arch Dermatol Res; 2011 Apr; 303(3):191-200. PubMed ID: 21132436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.
    Husain Z; FitzGerald GB; Wick MM
    J Invest Dermatol; 1990 Nov; 95(5):571-5. PubMed ID: 2121834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
    Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
    Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
    Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
    Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p21 loss cooperates with INK4 inactivation facilitating immortalization and Bcl-2-mediated anchorage-independent growth of oncogene-transduced primary mouse fibroblasts.
    Carbone CJ; Graña X; Reddy EP; Haines DS
    Cancer Res; 2007 May; 67(9):4130-7. PubMed ID: 17483323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
    D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
    Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
    Mitchell KO; El-Deiry WS
    Cell Growth Differ; 1999 Apr; 10(4):223-30. PubMed ID: 10319992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21.
    Baena E; Ortiz M; Martínez-A C; de Alborán IM
    Exp Hematol; 2007 Sep; 35(9):1333-43. PubMed ID: 17637497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAG2 is a target of the c-Myc gene and is involved in cellular senescence via the p21(CIP1) pathway.
    Zhang J; Lou X; Yang S; He S; Yang L; Liu M; Zhu H; Shan Q; Su S; Zhan Q; Xu N; Liu S
    Cancer Lett; 2012 May; 318(1):34-41. PubMed ID: 22146591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation.
    Carnero A; Beach DH
    Oncogene; 2004 Aug; 23(35):6006-11. PubMed ID: 15195145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin A but not cyclin D1 is essential for c-myc-modulated cell-cycle progression.
    Qi Y; Tu Y; Yang D; Chen Q; Xiao J; Chen Y; Fu J; Xiao X; Zhou Z
    J Cell Physiol; 2007 Jan; 210(1):63-71. PubMed ID: 17013808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc.
    Lee SG; Su ZZ; Emdad L; Sarkar D; Fisher PB
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17390-5. PubMed ID: 17088530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myc lacks E2F1's ability to suppress skin carcinogenesis.
    Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
    Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
    Seoane J; Le HV; Massagué J
    Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.
    Ji P; Zhou X; Liu Q; Fuller GN; Phillips LM; Zhang W
    Oncotarget; 2016 Apr; 7(17):23521-9. PubMed ID: 26993778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-Myc promotes tumor proliferation and anti‑apoptosis by repressing p21 in rhabdomyosarcomas.
    Zhang J; Song N; Zang D; Yu J; Li J; Di W; Guo R; Zhao W; Wang H
    Mol Med Rep; 2017 Oct; 16(4):4089-4094. PubMed ID: 28765944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis.
    Kangas A; Nicholson DW; Hölttä E
    Oncogene; 1998 Jan; 16(3):387-98. PubMed ID: 9467964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation.
    Braun K; Hölzl G; Soucek T; Geisen C; Möröy T; Hengstschläger M
    Oncogene; 1998 Oct; 17(17):2259-69. PubMed ID: 9811456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.